| Code | CSB-RA004847MB15HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to SRF-114, designed to specifically target CCR8 (C-C chemokine receptor type 8), a G protein-coupled receptor predominantly expressed on regulatory T cells (Tregs) and certain T helper cell subsets. CCR8 plays a critical role in immune cell trafficking and localization, particularly directing Tregs to tumor microenvironments where they suppress anti-tumor immunity. This receptor has emerged as a promising target in immuno-oncology research, as tumor-infiltrating Tregs often show elevated CCR8 expression compared to circulating Tregs, making it an attractive marker for selectively depleting immunosuppressive cells within the tumor while preserving peripheral immune homeostasis.
SRF-114 is a reference antibody that has been investigated for its ability to deplete CCR8-positive regulatory T cells in preclinical cancer models. This biosimilar provides researchers with a valuable tool for studying CCR8 biology, investigating Treg function in various disease contexts, and exploring therapeutic strategies aimed at modulating the tumor immune microenvironment. The antibody supports investigations into immunotherapy combinations and mechanisms of immune evasion in cancer research.
There are currently no reviews for this product.